The insurance model makes fertility treatments more affordable and accessible to millions of individuals and families.
Led by Highline Beta, the funding round included investments from Cartography Capital, Everywhere Ventures, and a strategic group of angel investors. The financial backing highlights the significant potential of Flora’s solution, which addresses a critical gap in reproductive healthcare financing.
Infertility affects 1 in 6 individuals worldwide, with treatment costs often exceeding $50,000 and most patients paying out of pocket. Flora Fertility’s insurance product offers a groundbreaking solution, allowing individuals to own and manage their fertility insurance independent of their employer, providing portability and flexibility.
Unlike traditional financing models, Flora’s approach is designed to make fertility treatment accessible regardless of a person’s employment or location.
“Our mission is simple: we want to make fertility care accessible and affordable for everyone,” said Laura J. McDonald, co-founder of Flora Fertility. “With our unique solution, women and families can proactively safeguard their reproductive future. The overwhelming response we’ve received demonstrates how deeply this resonates with future policyholders.”
Flora’s distribution network includes partnerships with women’s health apps, SMB employers, and embedded platforms, reaching over 10 million prospective parents across North America. The company is also a graduate of the InsurTech NY MGA Lab Fall 2023 cohort, solidifying its position as a leader in fertility insurance innovation.
With a founding team that brings expertise in data analytics, actuarial modeling, and financial services, Flora Fertility is set to revolutionize how fertility treatments are funded. Visit Flora at
“No one has created an individual risk model for fertility until now,” said Dr. Christy Lane, co-founder of Flora. “We’re proud to lead this innovation, leveraging our expertise in women’s health, data science, and actuarial modeling to deliver a solution that will fundamentally change how people finance fertility treatments, especially in underserved and underfunded markets.”
“We believe insurance can and should have a massive positive impact on people’s everyday lives and well-being. We’re excited to be able to innovate in this uncharted space,” said Somil Jain.
Investor support
Speaking about the decision to throw investment weight behind the fertility treatment space and help to expand employee benefits offerings, Flora’s funding partners also commented, with Marcus Daniels, Founding Partner and CEO of Highline Beta, saying: “Flora Fertility’s founders are boldly making a huge impact in women’s health with an innovative insurance solution. Fantastic to see the high investor & strategic engagement beyond Highline Beta’s venture studio support to further validate their exponential potential.”
Ben Stein, General Partner at Cartography Capital, said: “Every journey to parenthood is unique and Flora is a product that people need, and insurance underwriters want. We’re long overdue for underwriting models and insurance products created specifically for women, by women.”
Jenny Fielding, Co-Founder & Managing Partner at Everywhere Ventures, remarked: “Flora Fertility is democratising access to fertility care, and this aligns with our thesis around a more fragmented future of work. There is growing demand for personalised health coverage, especially in a work environment where not everyone works at a Fortune 500 company.
She added: We’re proud to back a world positive company that’s making critical health benefits more accessible for people, and that aligns with how they want to work today, and in the future.”
Source: PRNewswire
